Home/Filings/4/0001062993-24-002841
4//SEC Filing

CRANDELL KEITH 4

Accession 0001062993-24-002841

CIK 0001770121other

Filed

Feb 11, 7:00 PM ET

Accepted

Feb 12, 5:43 PM ET

Size

15.6 KB

Accession

0001062993-24-002841

Insider Transaction Report

Form 4
Period: 2024-02-08
Transactions
  • Purchase

    Common Stock

    2024-02-08$5.50/sh+363,637$2,000,00410,667,387 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2024-02-08$5.50/sh+727,272$3,999,99612,446,022 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2024-02-08$5.50/sh+727,272$3,999,99612,446,022 total(indirect: See Footnote)
Holdings
  • Common Stock

    (indirect: See Footnote)
    10,301,250
GILLIS STEVEN
10% Owner
Transactions
  • Purchase

    Common Stock

    2024-02-08$5.50/sh+727,272$3,999,99612,446,022 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2024-02-08$5.50/sh+363,637$2,000,00410,667,387 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2024-02-08$5.50/sh+727,272$3,999,99612,446,022 total(indirect: See Footnote)
Holdings
  • Common Stock

    (indirect: See Footnote)
    10,301,250
Transactions
  • Purchase

    Common Stock

    2024-02-08$5.50/sh+363,637$2,000,00410,667,387 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2024-02-08$5.50/sh+727,272$3,999,99612,446,022 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2024-02-08$5.50/sh+727,272$3,999,99612,446,022 total(indirect: See Footnote)
Holdings
  • Common Stock

    (indirect: See Footnote)
    10,301,250
BYBEE CLINTON
10% Owner
Transactions
  • Purchase

    Common Stock

    2024-02-08$5.50/sh+363,637$2,000,00410,667,387 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2024-02-08$5.50/sh+727,272$3,999,99612,446,022 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2024-02-08$5.50/sh+727,272$3,999,99612,446,022 total(indirect: See Footnote)
Holdings
  • Common Stock

    (indirect: See Footnote)
    10,301,250
Footnotes (6)
  • [F1]Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX.
  • [F2]Represents shares held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage). ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage.
  • [F3]ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein.
  • [F4]Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X.
  • [F5]Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
  • [F6]ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein.

Issuer

Sana Biotechnology, Inc.

CIK 0001770121

Entity typeother

Related Parties

1
  • filerCIK 0001219039

Filing Metadata

Form type
4
Filed
Feb 11, 7:00 PM ET
Accepted
Feb 12, 5:43 PM ET
Size
15.6 KB